Guidance and quality standards Awaiting development

Skip to filters Skip to results

Showing 1 to 10 of 29

lung cancerRemove lung cancer filter
Type: GuidanceRemove Type: Guidance filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance and quality standards awaiting development
Title	Type
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]	Technology appraisal guidance
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]	Technology appraisal guidance
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]	Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy TS ID 11840	Technology appraisal guidance
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073]	Technology appraisal guidance
Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer (Review of TA662) [ID6404]	Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]	Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]	Technology appraisal guidance
Encorafenib with binimetinib for treating BRAF V600E mutation-positive metastatic non-small-cell lung cancer [ID6177]	Technology appraisal guidance

Results per page

10
25
50
All